Could a pill replace chemo for advanced breast cancer? new trial aims to find out.
NCT ID NCT07615751
First seen Jun 04, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 3 trial compares an all-oral drug combination (pyrotinib, trastuzumab, and dalpiciclib) against standard chemotherapy plus targeted drugs for advanced HER2-positive breast cancer. About 502 patients who have had at most one prior treatment will be enrolled. The goal is to see if the oral regimen works as well as chemo but with fewer side effects and greater convenience.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyrotinib, trastuzumab, dalpiciclib
What this could lead to
If successful, this could offer a more convenient and less toxic oral treatment option for advanced HER2-positive breast cancer, potentially replacing chemotherapy.
What could go wrong
This is a non-inferiority trial, so the oral combo may prove no better than chemo and could still fail to control the disease. Side effects from the new drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.